Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

September 22, 2023 updated by: Richard Bloomer, University of Memphis

Randomized Trial to Assess the Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

The nutrient composition of this product is similar to the existing Liquid IV "hydration multiplier" product already on the market but with the addition of amino acids. With such low quantities of amino acids, in particular as compared to the amounts consumed in normal diets, there is no reason to believe that the product would cause any adverse outcomes. However, since no research has been done on the safety of regular consumption of this product, this study will evaluate the safety of the product with regards to routing blood chemistries and other variables. Specifically, standard testing will be performed including a measurement of vital signs, comprehensive metabolic panel, hematology panel, urinalysis, and quantification of triiodothyronine, thyroxine, and thyroid stimulating hormone. A questionnaire will also be used to assess product tolerability.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Maintaining adequate hydration is essential to optimal health, as well as athletic performance. When individuals exercise (in particular in a warm environment), they can lose excessive amounts of fluids along with necessary electrolytes (e.g., sodium, potassium, chloride) through sweating. With dehydration, individuals may feel sluggish and can experience impaired physical performance.

The use of electrolytes (sodium in particular) has been used for decades to aid athlete hydration and has led to the development of various sport drinks (e.g., Gatorade, Powerade) -which also include small amounts of carbohydrate. The addition of amino acids to electrolyte solutions has previously been demonstrated to further increase the transport of water and sodium from the jejunum (small intestine). Separate research also showed an amino acid and electrolyte drink increased cellular hydration compared to flavored water and electrolyte only drinks. A 2019 study found that amino acids hydration increased beverage hydration index (BHI)-a measure of fluid balance following consumption of a beverage and was age dependent.

Amino acids supplementation has been popular for some time among athletes due to other potential performance benefits including changes to anabolic hormone levels, alterations to energy consumption, and mental endurance. Further, amino acids may reduce post-exercise muscle soreness and aid in recovery.

The electrolyte amino-acid test product is a powder provided in individual stick packs and contains L-Alanine and L-Glutamine as well as 5 essential vitamins including Vitamins B3, B5, B6, B12 and Vitamin C. It is gluten-, soy-, and dairy-free, and provides electrolytes well below the daily value. The daily value (DV) tells us how much a particular nutrient in a serving of a food product contributes to a daily diet, based on a standard 2000 calorie diet. Despite what the name suggests, this product is taken orally, not intravenously. Liquid IV packets contain: sodium (510 mg, 22%DV) and potassium (380 mg, 8%DV). These packets contain a small percentage of the needed total electrolytes but adequate amounts to replace lost electrolytes as a result of physical activity.

The nutrient composition of this product is similar to the existing Liquid IV "hydration multiplier" product already on the market but with the addition of amino acids. With such low quantities of amino acids, in particular as compared to the amounts consumed in normal diets, there is no reason to believe that the product would cause any adverse outcomes. However, since no research has been done on the safety of regular consumption of this product, this study will evaluate the safety of the product with regards to routing blood chemistries and other variables. Specifically, standard testing will be performed including a measurement of vital signs, comprehensive metabolic panel, hematology panel, urinalysis, and quantification of triiodothyronine, thyroxine, and thyroid stimulating hormone. A questionnaire will also be used to assess product tolerability.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Tennessee
      • Memphis, Tennessee, United States, 38152
        • Center for Nutraceutical and Dietary Supplement Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Body mass index (BMI) between 18-29.9 kg/m2
  • able to fast overnight

Exclusion Criteria:

  • tobacco user
  • history of heart disease/cardiovascular disease
  • hypertensive (140/90 mmHg or less)
  • diabetes
  • history of immune disorder
  • history of kidney disease
  • hepatic impairment or disease
  • history of unstable thyroid
  • abnormality or obstruction of the gastrointestinal tract precluding swallowing
  • abnormal digestion conditions
  • previously diagnosed major affective disorder
  • psychiatric disorder that required hospitalization in prior year
  • history of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening)
  • no known sensitivity or allergy to any of the study products
  • consumption of alcohol-containing beverages within 24 hours of testing
  • consumption of caffeine-containing beverages within 24 hours of testing
  • active infection or illness of any kind
  • if female, lactating, pregnant, or planning to become pregnant during the study
  • receipt or use of an investigational product in another research study or change in medication, dietary supplementation, or significant change in diet/exercise regimen within 28 days prior to baseline/visit 2

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo once daily
1 stick pack dissolved in water once daily prior to breakfast
Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
Experimental: Test beverage once daily
1 stick pack dissolved in water once daily prior to breakfast
Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
Experimental: Test beverage twice daily
2 stick packs dissolved in water, one packet at a time twice daily (after lunch and after dinner)
Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
Experimental: Test beverage three times daily
3 stick packs dissolved in water, one packet at a time three times daily (after breakfast, lunch, and dinner)
Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Alanine transaminase
Time Frame: baseline
Alanine transaminase measured as part of metabolic panel with units IU/L
baseline
Alanine transaminase
Time Frame: 2 weeks of assigned treatment
Alanine transaminase measured as part of metabolic panel with units IU/L
2 weeks of assigned treatment
Alanine transaminase
Time Frame: 4 weeks of assigned treatment
Alanine transaminase measured as part of metabolic panel with units IU/L
4 weeks of assigned treatment
Aspartate transferase
Time Frame: baseline
Aspartate transferase measured as part of comprehensive metabolic panel with units IU/L
baseline
Aspartate transferase
Time Frame: 2 weeks of assigned treatment
Aspartate transferase measured as part of comprehensive metabolic panel with units IU/L
2 weeks of assigned treatment
Aspartate transferase
Time Frame: 4 weeks of assigned treatment
Aspartate transferase measured as part of comprehensive metabolic panel with units IU/L
4 weeks of assigned treatment
Albumin
Time Frame: baseline
Albumin measured as part of comprehensive metabolic panel with units g/dL
baseline
Albumin
Time Frame: 2 weeks of assigned treatment
Albumin measured as part of comprehensive metabolic panel with units g/dL
2 weeks of assigned treatment
Albumin
Time Frame: 4 weeks of assigned treatment
Albumin measured as part of comprehensive metabolic panel with units g/dL
4 weeks of assigned treatment
Alkaline phosphatase
Time Frame: baseline
Alkaline phosphatase measured as part of comprehensive metabolic panel with units IU/L
baseline
Alkaline phosphatase
Time Frame: 2 weeks of assigned treatment
Alkaline phosphatase measured as part of comprehensive metabolic panel with units IU/L
2 weeks of assigned treatment
Alkaline phosphatase
Time Frame: 4 weeks of assigned treatment
Alkaline phosphatase measured as part of comprehensive metabolic panel with units IU/L
4 weeks of assigned treatment
total bilirubin
Time Frame: baseline
total bilirubin measured as part of comprehensive metabolic panel with units mg/dL
baseline
total bilirubin
Time Frame: 2 weeks of assigned treatment
total bilirubin measured as part of comprehensive metabolic panel with units mg/dL
2 weeks of assigned treatment
total bilirubin
Time Frame: 4 weeks of assigned treatment
total bilirubin measured as part of comprehensive metabolic panel with units mg/dL
4 weeks of assigned treatment
blood urea nitrogen mg/dL
Time Frame: baseline
blood urea nitrogen as part of comprehensive metabolic panel with unite
baseline
blood urea nitrogen
Time Frame: 2 weeks of assigned treatment
blood urea nitrogen as part of comprehensive metabolic panel with units mg/dL
2 weeks of assigned treatment
blood urea nitrogen
Time Frame: 4 weeks of assigned treatment
blood urea nitrogen as part of comprehensive metabolic panel with units mg/dL
4 weeks of assigned treatment
calcium
Time Frame: baseline
calcium as part of comprehensive metabolic panel with units mg/dL
baseline
calcium
Time Frame: 2 weeks of assigned treatment
calcium as part of comprehensive metabolic panel with units mg/dL
2 weeks of assigned treatment
calcium
Time Frame: 4 weeks of assigned treatment
calcium as part of comprehensive metabolic panel with units mg/dL
4 weeks of assigned treatment
carbon dioxide
Time Frame: baseline
carbon dioxide as part of comprehensive metabolic panel with units mmol/L
baseline
carbon dioxide
Time Frame: 2 weeks of assigned treatment
carbon dioxide as part of comprehensive metabolic panel with units mmol/L
2 weeks of assigned treatment
carbon dioxide
Time Frame: 4 weeks of assigned treatment
carbon dioxide as part of comprehensive metabolic panel with units mmol/L
4 weeks of assigned treatment
chloride
Time Frame: baseline
chloride as part of comprehensive metabolic panel with units mmol/L
baseline
chloride
Time Frame: 2 weeks of assigned treatment
chloride as part of comprehensive metabolic panel with units mmol/L
2 weeks of assigned treatment
chloride
Time Frame: 4 weeks of assigned treatment
chloride as part of comprehensive metabolic panel with units mmol/L
4 weeks of assigned treatment
creatinine
Time Frame: baseline
creatinine as part of comprehensive metabolic panel with units mg/dL
baseline
creatinine
Time Frame: 2 weeks of assigned treatment
creatinine as part of comprehensive metabolic panel with units mg/dL
2 weeks of assigned treatment
creatinine
Time Frame: 4 weeks of assigned treatment
creatinine as part of comprehensive metabolic panel with units mg/dL
4 weeks of assigned treatment
estimated glomerular filtration rate calculation
Time Frame: baseline
estimated glomerular filtration rate calculation as part of comprehensive metabolic panel with units mL/min/1.73
baseline
estimated glomerular filtration rate calculation
Time Frame: 2 weeks of assigned treatment
estimated glomerular filtration rate calculation as part of comprehensive metabolic panel with units mL/min/1.73
2 weeks of assigned treatment
estimated glomerular filtration rate calculation
Time Frame: 4 weeks of assigned treatment
estimated glomerular filtration rate calculation as part of comprehensive metabolic panel with units mL/min/1.73
4 weeks of assigned treatment
blood glucose
Time Frame: baseline
glucose as part of comprehensive metabolic panel with units mg/dL
baseline
blood glucose
Time Frame: 2 weeks of assigned treatment
glucose as part of comprehensive metabolic panel with units mg/dL
2 weeks of assigned treatment
blood glucose
Time Frame: 4 weeks of assigned treatment
glucose as part of comprehensive metabolic panel with units mg/dL
4 weeks of assigned treatment
potassium
Time Frame: baseline
potassium as part of comprehensive metabolic panel with units mmol/L
baseline
potassium
Time Frame: 2 weeks of assigned treatment
potassium as part of comprehensive metabolic panel with units mmol/L
2 weeks of assigned treatment
potassium
Time Frame: 4 weeks of assigned treatment
potassium as part of comprehensive metabolic panel with units mmol/L
4 weeks of assigned treatment
total protein as part of comprehensive metabolic panel with units g/dL
Time Frame: baseline
total protein
baseline
total protein as part of comprehensive metabolic panel with units g/dL
Time Frame: 2 weeks of assigned treatment
total protein
2 weeks of assigned treatment
total protein as part of comprehensive metabolic panel with units g/dL
Time Frame: 4 weeks of assigned treatment
total protein
4 weeks of assigned treatment
sodium
Time Frame: baseline
sodium as part of comprehensive metabolic panel with units mmol/L
baseline
sodium
Time Frame: 2 weeks of assigned treatment
sodium as part of comprehensive metabolic panel with units mmol/L
2 weeks of assigned treatment
sodium
Time Frame: 4 weeks of assigned treatment
sodium as part of comprehensive metabolic panel with units mmol/L
4 weeks of assigned treatment
total globulin
Time Frame: baseline
total globulin as part of comprehensive metabolic panel with units g/dL
baseline
total globulin
Time Frame: 2 weeks of assigned treatment
total globulin as part of comprehensive metabolic panel with units g/dL
2 weeks of assigned treatment
total globulin
Time Frame: 4 weeks of assigned treatment
total globulin as part of comprehensive metabolic panel with units g/dL
4 weeks of assigned treatment
albumin/globulin ratio
Time Frame: baseline
albumin/globulin ratio as part of comprehensive metabolic panel
baseline
albumin/globulin ratio
Time Frame: 2 weeks of assigned treatment
albumin/globulin ratio as part of comprehensive metabolic panel
2 weeks of assigned treatment
albumin/globulin ratio
Time Frame: 4 weeks of assigned treatment
albumin/globulin ratio as part of comprehensive metabolic panel
4 weeks of assigned treatment
blood urea nitrogen/creatinine ratio
Time Frame: baseline
blood urea nitrogen/creatinine ratio as part of comprehensive metabolic panel
baseline
blood urea nitrogen/creatinine ratio
Time Frame: 2 weeks of assigned treatment
blood urea nitrogen/creatinine ratio as part of comprehensive metabolic panel
2 weeks of assigned treatment
blood urea nitrogen/creatinine ratio
Time Frame: 4 weeks of assigned treatment
blood urea nitrogen/creatinine ratio as part of comprehensive metabolic panel
4 weeks of assigned treatment
Hematocrit
Time Frame: baseline
Hematocrit as part of complete blood count panel with differential test measured as percentage
baseline
Hematocrit
Time Frame: 2 weeks of assigned treatment
Hematocrit as part of complete blood count panel with differential test measured as percentage
2 weeks of assigned treatment
Hematocrit
Time Frame: 4 weeks of assigned treatment
Hematocrit as part of complete blood count panel with differential test measured as percentage
4 weeks of assigned treatment
hemoglobin
Time Frame: baseline
hemoglobin as part of complete blood count panel with differential test measured as g/dL
baseline
hemoglobin
Time Frame: 2 weeks of assigned treatment
hemoglobin as part of complete blood count panel with differential test measured as g/dL
2 weeks of assigned treatment
hemoglobin
Time Frame: 4 weeks of assigned treatment
hemoglobin as part of complete blood count panel with differential test measured as g/dL
4 weeks of assigned treatment
mean corpuscular volume
Time Frame: baseline
mean corpuscular volume as part of complete blood count panel with differential test measured as femtoliter
baseline
mean corpuscular volume
Time Frame: 2 weeks of assigned treatment
mean corpuscular volume as part of complete blood count panel with differential test measured as femtoliter
2 weeks of assigned treatment
mean corpuscular volume
Time Frame: 4 weeks of assigned treatment
mean corpuscular volume as part of complete blood count panel with differential test measured as femtoliter
4 weeks of assigned treatment
mean corpuscular hemoglobin concentration
Time Frame: baseline
mean corpuscular hemoglobin concentration as part of complete blood count panel with differential test measured as g/dL
baseline
mean corpuscular hemoglobin concentration
Time Frame: 2 weeks of assigned treatment
mean corpuscular hemoglobin concentration as part of complete blood count panel with differential test measured as g/dL
2 weeks of assigned treatment
mean corpuscular hemoglobin concentration
Time Frame: 4 weeks of assigned treatment
mean corpuscular hemoglobin concentration as part of complete blood count panel with differential test measured as g/dL
4 weeks of assigned treatment
White blood cell distribution (absolute)
Time Frame: baseline
absolute measures of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes per microliter as part of complete blood count panel
baseline
White blood cell distribution (absolute)
Time Frame: 2 weeks of assigned treatment
absolute measures of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes per microliter as part of complete blood count panel
2 weeks of assigned treatment
White blood cell distribution (absolute)
Time Frame: 4 weeks of assigned treatment
absolute measures of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes per microliter as part of complete blood count panel
4 weeks of assigned treatment
White blood cell distribution (percentage)
Time Frame: baseline
percentages of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes out of total white blood cells.
baseline
White blood cell distribution (percentage)
Time Frame: 2 weeks of assigned treatment
percentages of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes out of total white blood cells.
2 weeks of assigned treatment
White blood cell distribution (percentage)
Time Frame: 4 weeks of assigned treatment
percentages of white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes out of total white blood cells.
4 weeks of assigned treatment
Red cell distribution width
Time Frame: baseline
red cell distribution width as part of complete blood count panel with differential test measured as percentage
baseline
Red cell distribution width
Time Frame: 2 weeks of assigned treatment
red cell distribution width as part of complete blood count panel with differential test measured as percentage
2 weeks of assigned treatment
Red cell distribution width
Time Frame: 4 weeks of assigned treatment
red cell distribution width as part of complete blood count panel with differential test measured as percentage
4 weeks of assigned treatment
platelet count
Time Frame: baseline
platelet count per microliter as part of complete blood count panel with differential test
baseline
platelet count
Time Frame: 2 weeks of assigned treatment
platelet count per microliter as part of complete blood count panel with differential test
2 weeks of assigned treatment
platelet count
Time Frame: 4 weeks of assigned treatment
platelet count per microliter as part of complete blood count panel with differential test
4 weeks of assigned treatment
red cell count
Time Frame: baseline
red cell count per microliter as part of complete blood count panel with differential test
baseline
red cell count
Time Frame: 2 weeks of assigned treatment
red cell count per microliter as part of complete blood count panel with differential test
2 weeks of assigned treatment
red cell count
Time Frame: 4 weeks of assigned treatment
red cell count per microliter as part of complete blood count panel with differential test
4 weeks of assigned treatment
white cell count
Time Frame: baseline
white cell count per microliter as part of complete blood count panel with differential test
baseline
white cell count
Time Frame: 2 weeks of assigned treatment
white cell count per microliter as part of complete blood count panel with differential test
2 weeks of assigned treatment
white cell count
Time Frame: 4 weeks of assigned treatment
white cell count per microliter as part of complete blood count panel with differential test
4 weeks of assigned treatment
Triiodothyronine
Time Frame: baseline
Triiodothyronine measured in blood as ng/dL
baseline
Triiodothyronine
Time Frame: 2 weeks of assigned treatment
Triiodothyronine measured in blood as ng/dL
2 weeks of assigned treatment
Triiodothyronine
Time Frame: 4 weeks of assigned treatment
Triiodothyronine measured in blood as ng/dL
4 weeks of assigned treatment
Thyroxine
Time Frame: baseline
Thyroxine measured in blood as ug/dL
baseline
Thyroxine
Time Frame: 2 weeks of assigned treatment
Thyroxine ug/dL measured in blood as ug/dL
2 weeks of assigned treatment
Thyroxine
Time Frame: 4 weeks of assigned treatment
Thyroxine ug/dL measured in blood as ug/dL
4 weeks of assigned treatment
thyroid stimulating hormone
Time Frame: baseline
Thyroxine measured in blood as micro-IU/dL
baseline
thyroid stimulating hormone
Time Frame: 2 weeks of assigned treatment
Thyroxine measured in blood as micro-IU/dL
2 weeks of assigned treatment
thyroid stimulating hormone
Time Frame: 4 weeks of assigned treatment
Thyroxine measured in blood as micro-IU/dL
4 weeks of assigned treatment
Urine Color
Time Frame: baseline
Urine color as reported in complete urinalysis
baseline
Urine Color
Time Frame: 2 weeks of assigned treatment
Urine color as reported in complete urinalysis
2 weeks of assigned treatment
Urine Color
Time Frame: 4 weeks of assigned treatment
Urine color as reported in complete urinalysis
4 weeks of assigned treatment
Urine appearance
Time Frame: baseline
Urine appearance as reported in complete urinalysis
baseline
Urine appearance
Time Frame: 2 weeks of assigned treatment
Urine appearance as reported in complete urinalysis
2 weeks of assigned treatment
Urine appearance
Time Frame: 4 weeks of assigned treatment
Urine appearance as reported in complete urinalysis
4 weeks of assigned treatment
Urine specific gravity
Time Frame: baseline
Urine specific gravity as reported in complete urinalysis
baseline
Urine specific gravity
Time Frame: 2 weeks of assigned treatment
Urine specific gravity as reported in complete urinalysis
2 weeks of assigned treatment
Urine specific gravity
Time Frame: 4 weeks of assigned treatment
Urine specific gravity as reported in complete urinalysis
4 weeks of assigned treatment
Urine potential of hydrogen
Time Frame: baseline
Urine potential of hydrogen (pH) as reported in complete urinalysis
baseline
Urine potential of hydrogen
Time Frame: 2 weeks of assigned treatment
Urine potential of hydrogen (pH) as reported in complete urinalysis
2 weeks of assigned treatment
Urine potential of hydrogen
Time Frame: 4 weeks of assigned treatment
Urine potential of hydrogen (pH) as reported in complete urinalysis
4 weeks of assigned treatment
Protein in urine
Time Frame: baseline
Protein, if present, measured in urine in complete urinalysis
baseline
Protein in urine
Time Frame: 2 weeks of assigned treatment
Protein, if present, measured in urine in complete urinalysis
2 weeks of assigned treatment
Protein in urine
Time Frame: 4 weeks of assigned treatment
Protein, if present, measured in urine in complete urinalysis
4 weeks of assigned treatment
Glucose in urine
Time Frame: baseline
Glucose, if present, measured in urine in complete urinalysis
baseline
Glucose in urine
Time Frame: 2 weeks of assigned treatment
Glucose, if present, measured in urine in complete urinalysis
2 weeks of assigned treatment
Glucose in urine
Time Frame: 4 weeks of assigned treatment
Glucose, if present, measured in urine in complete urinalysis
4 weeks of assigned treatment
Ketones in urine
Time Frame: baseline
Ketones, if present, measured in urine in complete urinalysis
baseline
Ketones in urine
Time Frame: 2 weeks of assigned treatment
Ketones, if present, measured in urine in complete urinalysis
2 weeks of assigned treatment
Ketones in urine
Time Frame: 4 weeks of assigned treatment
Ketones, if present, measured in urine in complete urinalysis
4 weeks of assigned treatment
Occult blood in urine
Time Frame: baseline
Occult blood, if present, measured in urine in complete urinalysis
baseline
Occult blood in urine
Time Frame: 2 weeks of assigned treatment
Occult blood, if present, measured in urine in complete urinalysis
2 weeks of assigned treatment
Occult blood in urine
Time Frame: 4 weeks of assigned treatment
Occult blood, if present, measured in urine in complete urinalysis
4 weeks of assigned treatment
White blood cell esterase in urine
Time Frame: baseline
White blood cell esterase, if present, measured in urine
baseline
White blood cell esterase in urine
Time Frame: 2 weeks of assigned treatment
White blood cell esterase, if present, measured in urine
2 weeks of assigned treatment
White blood cell esterase in urine
Time Frame: 4 weeks of assigned treatment
White blood cell esterase, if present, measured in urine
4 weeks of assigned treatment
Urine nitrite
Time Frame: baseline
nitrite, if present, measured in urine
baseline
Urine nitrite
Time Frame: 2 weeks of assigned treatment
nitrite, if present, measured in urine
2 weeks of assigned treatment
Urine nitrite
Time Frame: 4 weeks of assigned treatment
nitrite, if present, measured in urine
4 weeks of assigned treatment
bilirubin in urine
Time Frame: baseline
bilirubin, if present, measured in urine
baseline
bilirubin in urine
Time Frame: 2 weeks of assigned treatment
bilirubin, if present, measured in urine
2 weeks of assigned treatment
bilirubin in urine
Time Frame: 4 weeks of assigned treatment
bilirubin, if present, measured in urine
4 weeks of assigned treatment
urobilinogen in urine
Time Frame: baseline
urobilinogen in urine measured in urinalysis as mg/dL
baseline
urobilinogen in urine
Time Frame: 2 weeks of assigned treatment
urobilinogen in urine measured in urinalysis as mg/dL
2 weeks of assigned treatment
urobilinogen in urine
Time Frame: 4 weeks of assigned treatment
urobilinogen in urine measured in urinalysis as mg/dL
4 weeks of assigned treatment
Heart Rate
Time Frame: baseline
Heart Rate measured using an automated blood pressure machine
baseline
Heart Rate
Time Frame: 2 weeks of assigned treatment
Heart rate measured using an automated blood pressure machine
2 weeks of assigned treatment
Heart Rate
Time Frame: 4 weeks of assigned treatment
Heart rate measured using an automated blood pressure machine
4 weeks of assigned treatment
Blood Pressure
Time Frame: baseline
Systolic and Diastolic blood pressure measured using an automated blood pressure machine
baseline
Blood Pressure
Time Frame: 2 weeks of assigned treatment
Systolic and Diastolic blood pressure measured using an automated blood pressure machine
2 weeks of assigned treatment
Blood Pressure
Time Frame: 4 weeks of assigned treatment
Systolic and Diastolic blood pressure measured using an automated blood pressure machine
4 weeks of assigned treatment
Product Tolerability questionnaire (gastrointestinal)
Time Frame: baseline
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the past two weeks from 0 (None) to 10 (severe)
baseline
Product Tolerability questionnaire (gastrointestinal)
Time Frame: 2 weeks of assigned treatment
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the past two weeks from 0 (None) to 10 (severe)
2 weeks of assigned treatment
Product Tolerability questionnaire (gastrointestinal)
Time Frame: 4 weeks of assigned treatment
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the past two weeks from 0 (None) to 10 (severe)
4 weeks of assigned treatment
Product Tolerability questionnaire (consumption)
Time Frame: baseline
Questionnaire that can be scored 1-5 (1 bad quality to 5 good quality): answers of strongly agree, agree, neutral, disagree, and strongly agree for tastes pleasant, easy to drink, easy on stomach, would purchase, dissolves easily, too gritty, too sticky and excessively, mildly too much, optimal, mildly too little, and extremely lacking for sweet, sour, salty, bitter. Final question on after taste with answers of pleasant, ok, no taste, unpleasant, extremely unpleasant.
baseline
Product Tolerability questionnaire (consumption)
Time Frame: 2 weeks of assigned treatment
Questionnaire that can be scored 1-5 (1 bad quality to 5 good quality): with answers of strongly agree, agree, neutral, disagree, and strongly agree for tastes pleasant, easy to drink, easy on stomach, would purchase, dissolves easily, too gritty, too sticky and excessively, mildly too much, optimal, mildly too little, and extremely lacking for sweet, sour, salty, bitter. Final question on after taste with answers of pleasant, ok, no taste, unpleasant, extremely unpleasant.
2 weeks of assigned treatment
Product Tolerability questionnaire (consumption)
Time Frame: 4 weeks of assigned treatment visit
Questionnaire that can be scored 1-5 (1 bad quality to 5 good quality): with answers of strongly agree, agree, neutral, disagree, and strongly agree for tastes pleasant, easy to drink, easy on stomach, would purchase, dissolves easily, too gritty, too sticky and excessively, mildly too much, optimal, mildly too little, and extremely lacking for sweet, sour, salty, bitter. Final question on after taste with answers of pleasant, ok, no taste, unpleasant, extremely unpleasant.
4 weeks of assigned treatment visit
tolerability questionnaire
Time Frame: 3 days before baseline visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
3 days before baseline visit
Daily food diary
Time Frame: 3 days before baseline visit
A list of all food and drink consumed that day
3 days before baseline visit
tolerability questionnaire
Time Frame: 2 days before baseline visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
2 days before baseline visit
Daily food diary
Time Frame: 2 days before baseline visit
A list of all food and drink consumed that day
2 days before baseline visit
tolerability questionnaire
Time Frame: 1 day before baseline visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
1 day before baseline visit
Daily food diary
Time Frame: 1 day before baseline visit
A list of all food and drink consumed that day
1 day before baseline visit
tolerability questionnaire
Time Frame: 3 days before 2 week visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
3 days before 2 week visit
Daily food diary
Time Frame: 3 days before 2 week visit
A list of all food and drink consumed that day
3 days before 2 week visit
Daily food diary
Time Frame: 2 days before 2 week visit
A list of all food and drink consumed that day
2 days before 2 week visit
tolerability questionnaire
Time Frame: 2 days before 2 week visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
2 days before 2 week visit
tolerability questionnaire
Time Frame: 1 day before 2 week visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
1 day before 2 week visit
Daily food diary
Time Frame: 1 day before 2 week visit
A list of all food and drink consumed that day
1 day before 2 week visit
tolerability questionnaire
Time Frame: 3 days before 4 week visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
3 days before 4 week visit
Daily food diary
Time Frame: 3 days before 4 week visit
A list of all food and drink consumed that day
3 days before 4 week visit
tolerability questionnaire
Time Frame: 2 days before 4 week visit
A list of all food and drink consumed that day along with a Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
2 days before 4 week visit
Daily food diary
Time Frame: 2 days before 4 week visit
A list of all food and drink consumed that day
2 days before 4 week visit
tolerability questionnaire
Time Frame: 1 day before 4 week visit
Visual analog scale used to assess gastrointestinal issues (bloating, constipation, diarrhea, frequent urination, gas, nausea, stomach fullness, abdominal pain/cramping) over the day (None) to 10 (severe)
1 day before 4 week visit
Daily food diary
Time Frame: 1 day before 4 week visit
A list of all food and drink consumed that day
1 day before 4 week visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Richard Bloomer, PhD, University of Memphis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2022

Primary Completion (Actual)

July 14, 2023

Study Completion (Actual)

July 18, 2023

Study Registration Dates

First Submitted

October 17, 2022

First Submitted That Met QC Criteria

October 21, 2022

First Posted (Actual)

October 25, 2022

Study Record Updates

Last Update Posted (Actual)

September 26, 2023

Last Update Submitted That Met QC Criteria

September 22, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • PRO-FY2023-5

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.